Khurana Vikas, Sheth Ankur, Caldito Gloria, Barkin Jamie S
Division of Gastroenterology and Hepatology, Overton Brooks Veterans Affairs Medical Center, Shreveport, LA 71101-4295, USA.
Pancreas. 2007 Mar;34(2):260-5. doi: 10.1097/MPA.0b013e318030e963.
Statins are commonly used cholesterol-lowering agents that are noted to suppress tumor cell growth in several in vitro and animal models.
We studied the association between pancreatic cancer and statins in veterans. A retrospective, nested case-control study was conducted using prospectively collected data from the Veterans Integrated Service Networks 16 Veteran Affairs database from 1998 to 2004. We analyzed data on 483,733 patients from 8 states located in south central United States. The primary variables of interest were pancreatic cancer and the use of statins before the diagnosis of pancreatic cancer. Multiple logistic regression analysis was done to adjust for covariates including age, sex, body mass index, smoking, diabetes, and race. The SAS software was used for statistical computing.
Of the 483,733 patients in the study, 163,467 (33.79%) were on statins, and 475 (0.098%) patients had a primary diagnosis of pancreatic cancer. Statin use of more than 6 months was associated with a risk reduction of pancreatic cancer of 67% (adjusted odds ratio, 0.33; 95% confidence interval, 0.26-0.41; P < 0.01).A dose-response relationship was noted between statin use and pancreatic cancer with an 80% risk reduction (adjusted odds ratio, 0.2; 95% confidence interval, 0.13-0.29; P < 0.01) with use of statin for more than 4 years. Furthermore, the protective effect of statin was seen across different age and racial groups, and was irrespective of the presence of diabetes, smoking, or alcohol use.
Statins seem to be protective against the development of pancreatic cancer, and the magnitude of the effect correlates with the duration of statin use.
他汀类药物是常用的降胆固醇药物，在多个体外和动物模型中均显示可抑制肿瘤细胞生长。
我们研究了退伍军人中胰腺癌与他汀类药物之间的关联。利用1998年至2004年从退伍军人综合服务网络16退伍军人事务数据库中前瞻性收集的数据进行了一项回顾性巢式病例对照研究。我们分析了来自美国中南部8个州的483,733名患者的数据。主要关注变量为胰腺癌以及胰腺癌诊断前他汀类药物的使用情况。进行了多因素逻辑回归分析以调整协变量，包括年龄、性别、体重指数、吸烟、糖尿病和种族。使用SAS软件进行统计计算。
在该研究的483,733名患者中，163,467名（33.79%）使用了他汀类药物，475名（0.098%）患者被初步诊断为胰腺癌。使用他汀类药物超过6个月与胰腺癌风险降低67%相关（校正比值比，0.33；95%置信区间，0.26 - 0.41；P < 0.01）。他汀类药物使用与胰腺癌之间存在剂量反应关系，使用他汀类药物超过4年时风险降低80%（校正比值比，0.2；95%置信区间，0.13 - 0.29；P < 0.01）。此外，他汀类药物的保护作用在不同年龄和种族组中均可见，且与糖尿病、吸烟或饮酒情况无关。
他汀类药物似乎对胰腺癌的发生具有保护作用，且这种作用的程度与他汀类药物的使用时长相关。
